Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.sabcs17-ot3-05-01 ◽

2018 ◽

Author(s):

B Overmoyer ◽

M Regan ◽

K Polyak ◽

J Brock ◽

C Van Poznak ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Inflammatory Breast Cancer ◽

Triple Negative ◽

Download Full-text

Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab /carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide (AC) for newly diagnosed primary triple-negative inflammatory breast cancer (TNIBC)

10.1158/1538-7445.sabcs17-ot3-06-04 ◽

2018 ◽

Author(s):

JS Willey ◽

CA Parker ◽

B Lim ◽

V Valero ◽

HT Le-Petross ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Inflammatory Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Newly Diagnosed ◽

Randomized Phase Ii

Download Full-text

Abstract OT1-02-01: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (MIBC) or non-IBC triple negative breast cancer (non-IBC TNBC) who have achieved clinical response or stable disease to prior chemotherapy

10.1158/1538-7445.sabcs17-ot1-02-01 ◽

2018 ◽

Author(s):

JS Willey ◽

CA Parker ◽

V Valero ◽

B Lim ◽

JM Reuben ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Response ◽

Phase Ii ◽

Inflammatory Breast Cancer ◽

Triple Negative Breast Cancer ◽

Stable Disease ◽

Triple Negative ◽

Phase Ii Study ◽

Prior Chemotherapy

Download Full-text

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2492-y ◽

2014 ◽

Vol 74 (2) ◽

pp. 229-238 ◽

Author(s):

N. Masuda ◽

K. Higaki ◽

T. Takano ◽

N. Matsunami ◽

T. Morimoto ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Hormone Receptor ◽

Primary Breast Cancer ◽

Triple Negative ◽

Download Full-text

A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04224922 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Stage Ii ◽

Weekly Paclitaxel ◽

Download Full-text

179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.460 ◽

2021 ◽

Vol 32 ◽

pp. S436

Author(s):

C. Wang ◽

Z. Liu ◽

X. Chen ◽

J. Qiao ◽

L. Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Open Label Phase

Download Full-text

Abstract PS11-32: Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ps11-32 ◽

2021 ◽

Author(s):

Erika Hamilton ◽

Arielle Lee ◽

Rachel Swart ◽

Gina Newton ◽

Brenda O'Connell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Locally Advanced ◽

Download Full-text

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Download Full-text

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line Treatment

Download Full-text

P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.

10.1158/0008-5472.sabcs11-p3-14-08 ◽

2011 ◽

Author(s):

ML Telli ◽

AW Kurian ◽

KC Jensen ◽

S Vinayak ◽

P Flaherty ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Triple Negative ◽

Download Full-text

Abstract OT2-1-03: A pilot and phase II study of entinostat and anastrozole/tamoxifen in women with triple negative breast cancer (TNBC) to evaluate biomarkers and surrogates for response

10.1158/1538-7445.sabcs14-ot2-1-03 ◽

2015 ◽

Author(s):

Saranya Chumsri ◽

Gauri Sabnis ◽

Nancy Tait ◽

Jane Lewis ◽

Emily Bellavance ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Download Full-text